Avenue Therapeutics Inc (NASDAQ: ATXI) is 8.63% higher on its value in year-to-date trading and has touched a low of $0.11 and a high of $1.36 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ATXI stock was last observed hovering at around $0.16 in the last trading session, with the day’s gains setting it 0.01%.
Currently trading at $0.17, the stock is 13.10% and 10.58% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.91 million and changing 7.96% at the moment leaves the stock -69.89% off its SMA200. ATXI registered -84.24% loss for a year compared to 6-month loss of -75.71%. The firm has a 200-day simple moving average (SMA200) of -$0.72.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 20.87% gain in the last 1 month and extending the period to 3 months gives it a 13.94%, and is 4.11% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.89% over the week and 10.09% over the month.
Avenue Therapeutics Inc (ATXI) has around 2 employees, a market worth around $6.53M and $0.00M in sales. Distance from 52-week low is 55.47% and -87.14% from its 52-week high.
Avenue Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.1.The EPS is expected to grow by 28.83% this year.
Avenue Therapeutics Inc (ATXI) Top Institutional Holders
18 institutions hold shares in Avenue Therapeutics Inc (ATXI), with institutional investors hold 3.81% of the company’s shares. The shares outstanding are 37.31M, and float is at 32.47M with Short Float at 0.50%. Institutions hold 3.32% of the Float.
The top institutional shareholder in the company is Sabby Management, LLC with over 0.55 million shares valued at $0.65 million. The investor’s holdings represent 6.17% of the ATXI Shares outstanding. As of Jun 29, 2023, the second largest holder is Bank Of New York Mellon Corporation with 52986.0 shares valued at $61993.0 to account for 0.59% of the shares outstanding. The other top investors are Geode Capital Management, LLC which holds 52571.0 shares representing 0.59% and valued at over $61508.0, while State Street Corporation holds 0.34% of the shares totaling 30593.0 with a market value of $35793.0.
Avenue Therapeutics Inc (ATXI) Insider Activity
The most recent transaction is an insider sale by Davidow Robert L,the company’s10% Owner. SEC filings show that Davidow Robert L sold 353,000 shares of the company’s common stock on Dec 11 ’23 at a price of $0.14 per share for a total of $49600.0. Following the sale, the insider now owns 22000.0 shares.
Avenue Therapeutics Inc disclosed in a document filed with the SEC on Dec 11 ’23 that Davidow Robert L (10% Owner) sold a total of 264,000 shares of the company’s common stock. The trade occurred on Dec 11 ’23 and was made at $0.14 per share for $36960.0. Following the transaction, the insider now directly holds 0.68 million shares of the ATXI stock.
Still, SEC filings show that on Sep 08 ’23, Fortress Biotech, Inc. (10% Owner) acquired 418,410 shares at an average price of $0.72 for $0.3 million. The insider now directly holds 1,032,390 shares of Avenue Therapeutics Inc (ATXI).
